Lidocaine Accord (Lidocaine Hydrochloride)

Lidocaine works by blocking voltage‑gated sodium channels on nerve and cardiac cells. This blockade prevents the rapid influx of sodium that is necessary for depolarization, thereby inhibiting the initiation and propagation of nerve impulses and suppressing abnormal cardiac electrical activity.

The dosage of Lidocaine Accord is determined by the prescribing clinician based on the specific indication, route of administration, patient weight, and clinical condition. Healthcare professionals calculate the appropriate dose and concentration to achieve the desired anesthetic or anti‑arrhythmic effect.

Safety data for Lidocaine Accord in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Lidocaine Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with longer‑acting agents such as bupivacaine, lidocaine provides a faster onset but a shorter duration of action, making it ideal for procedures requiring rapid, temporary anesthesia. Its safety profile is well‑established, though it may have a higher risk of systemic toxicity at high plasma concentrations than some newer agents.

Lidocaine Accord should be stored below 25 °C in its original packaging, protected from light and moisture. Do not freeze the solution. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if stored in a cooler environment.

Lidocaine Accord is administered by injection. For local anesthesia, it is infiltrated directly into the tissue surrounding the surgical site. For epidural analgesia, it is injected into the epidural space under sterile technique. Intravenous administration is reserved for cardiac indications and is given as a controlled infusion or bolus by qualified personnel.

The most serious risks include severe allergic reactions (anaphylaxis), cardiac conduction disturbances such as heart block or severe bradycardia, methemoglobinemia, and central nervous system toxicity that can lead to seizures or loss of consciousness. Immediate medical intervention is required if any of these events occur.

Lidocaine Accord should be avoided in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, in individuals with severe hepatic impairment without dose adjustment, and in patients with pre‑existing severe cardiac conduction abnormalities unless closely monitored. Use in pregnant or lactating women is only permitted when the expected benefit justifies potential risk.